Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
23 studies found for:    "methodist hospital" | Open Studies | "Lung Diseases" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy
Conditions: Lung Neoplasms;   Thoracic Neoplasms;   Neoplasms by Site;   Neoplasms;   Lung Diseases
Interventions: Device: MIMIG System;   Drug: Indocyanine Green (ICG)
2 Not yet recruiting Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma
Conditions: Lung Squamous Cell Carcinoma Stage IV;   Nonsquamous Nonsmall Cell Neoplasm of Lung
Interventions: Biological: ADV/HSV-tk;   Drug: Valacyclovir;   Radiation: SBRT;   Drug: nivolumab
3 Recruiting Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
Conditions: Pulmonary Hypertension;   Interstitial Lung Disease;   Combined Pulmonary Fibrosis and Emphysema
Interventions: Drug: Inhaled Treprostinil;   Drug: Placebo
4 Recruiting Beraprost-314d Added-on to Tyvaso® (BEAT)
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Beraprost Sodium 314d Modified Release Tablets;   Drug: Placebo
5 Recruiting Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
Condition: Pulmonary Hypertension
Interventions: Drug: Macitentan 10mg;   Drug: Placebo sugar pill
6 Recruiting A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ubenimex;   Other: placebo
7 Recruiting The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Macitentan;   Drug: Tadalafil;   Drug: Selexipag
8 Recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Conditions: Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IB Squamous Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIA Squamous Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIB Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Squamous Cell Lung Carcinoma
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
9 Recruiting Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
10 Recruiting Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Taselisib
11 Recruiting Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
12 Recruiting Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Palbociclib
13 Recruiting Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Drug: Docetaxel;   Biological: Durvalumab;   Drug: Erlotinib Hydrochloride;   Drug: FGFR Inhibitor AZD4547;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Palbociclib;   Biological: Rilotumumab;   Drug: Taselisib
14 Recruiting Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
Conditions: Adenosquamous Lung Carcinoma;   Bronchioloalveolar Carcinoma;   Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Non-Small Cell Lung Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride;   Drug: Paclitaxel;   Radiation: Volume Modulated Arc Therapy
15 Recruiting Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Crizotinib;   Other: Laboratory Biomarker Analysis;   Other: Placebo
16 Not yet recruiting Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
Conditions: Pulmonary Embolism;   Venous Thrombosis
Interventions: Drug: Enteric Coated Aspirin;   Drug: Warfarin;   Drug: Rivaroxaban
17 Recruiting Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST
Condition: Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Interventions: Drug: Placebo capsules;   Drug: Bardoxolone methyl capsules
18 Recruiting Cook IVC Filter Study
Condition: Pulmonary Embolism
Intervention: Device: Günther Tulip® Vena Cava Filter and Cook Celect® Vena Cava Filters
19 Recruiting Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Condition: Lung Cancer
Interventions: Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
20 Recruiting Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Biological: bevacizumab;   Drug: pemetrexed disodium

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.